These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 27636997

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
    Cuyàs E, Queralt B, Martin-Castillo B, Bosch-Barrera J, Menendez JA.
    Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
    [Abstract] [Full Text] [Related]

  • 3. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
    Yoon J, Koo KH, Choi KY.
    Cancer Res; 2011 Jan 15; 71(2):445-53. PubMed ID: 21118963
    [Abstract] [Full Text] [Related]

  • 4. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC.
    J Clin Oncol; 2012 May 01; 30(13):1505-12. PubMed ID: 22412142
    [Abstract] [Full Text] [Related]

  • 5. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A.
    Int J Cancer; 2015 Jan 01; 136(1):83-90. PubMed ID: 24806288
    [Abstract] [Full Text] [Related]

  • 6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.
    Int J Oncol; 2008 Dec 01; 33(6):1165-76. PubMed ID: 19020749
    [Abstract] [Full Text] [Related]

  • 7. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
    Mizukami T, Togashi Y, Sogabe S, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakajima TE, Boku N, Nishio K.
    Int J Oncol; 2015 Aug 01; 47(2):499-505. PubMed ID: 26081723
    [Abstract] [Full Text] [Related]

  • 8. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
    Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ.
    Sci Signal; 2011 Mar 29; 4(166):ra17. PubMed ID: 21447798
    [Abstract] [Full Text] [Related]

  • 9. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
    Hayes TK, Luo F, Cohen O, Goodale AB, Lee Y, Pantel S, Bagul M, Piccioni F, Root DE, Garraway LA, Meyerson M, Johannessen CM.
    Cancer Res; 2019 May 01; 79(9):2352-2366. PubMed ID: 30819666
    [Abstract] [Full Text] [Related]

  • 10. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
    Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G.
    Invest New Drugs; 2016 Apr 01; 34(2):168-75. PubMed ID: 26666244
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 01; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 12. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, Chen SJ, Yang TS.
    Oncotarget; 2016 Apr 19; 7(16):22257-70. PubMed ID: 26989027
    [Abstract] [Full Text] [Related]

  • 13. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 14. Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.
    Kan G, Wang Z, Sheng C, Chen G, Yao C, Mao Y, Chen S.
    Adv Sci (Weinh); 2021 May 03; 8(10):2004344. PubMed ID: 34026451
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C.
    Oncology; 2014 May 03; 87(1):7-20. PubMed ID: 24968756
    [Abstract] [Full Text] [Related]

  • 16. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E.
    Clin Cancer Res; 2014 Jul 15; 20(14):3775-86. PubMed ID: 24812410
    [Abstract] [Full Text] [Related]

  • 17. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK, Graab U, Fulda S.
    Cancer Lett; 2013 Sep 01; 337(2):200-9. PubMed ID: 23684925
    [Abstract] [Full Text] [Related]

  • 18. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
    Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R.
    Cancer Treat Rev; 2015 Sep 01; 41(8):653-9. PubMed ID: 26220150
    [Abstract] [Full Text] [Related]

  • 19. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 01; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.